The Latest Breaking News from Incyte

The stock market tested key levels but ultimately rallied, with many leaders flashing buy signals. Bitcoin raced toward $100,000.

Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.

Incyte sees its Relative Strength Rating hit the 80-plus level.

Incyte stock broke out Tuesday after sales of the company's two key products beat analysts' third-quarter projections.

Despite Incyte’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Dow Jones tech giant Intel led the S&P 500 Monday, and kept running late. Apple chipmakers Qorvo and Skyworks sold off on iPhone 16 concerns.

While Incyte has underperformed the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Value investing is highly favored as it focuses on purchasing undervalued stocks with solid fundamentals, providing the potential for high returns with lower risk and a disciplined, long-term approach. Therefore, it could be wise to invest in fundamentally sound, value stocks Expedia Group (EXPE), Incyte (INCY), and Albertsons Companies (ACI)…

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.